Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Neurocrine Biosciences stock

Learn how to easily invest in Neurocrine Biosciences stock.

Neurocrine Biosciences Inc is a drug manufacturers-specialty & generic business based in the US. Neurocrine Biosciences shares (NBIX) are listed on the NASDAQ and all prices are listed in US Dollars. Neurocrine Biosciences employs 1,100 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Neurocrine Biosciences

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – NBIX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Neurocrine Biosciences stock price (NASDAQ: NBIX)

Use our graph to track the performance of NBIX stocks over time.

Neurocrine Biosciences shares at a glance

Information last updated 2022-06-30.
Latest market close$99.25
52-week range$71.88 - $108.02
50-day moving average $90.90
200-day moving average $90.04
Wall St. target price$111.81
PE ratio 131.7297
Dividend yield $0 (0%)
Earnings per share (TTM) $0.74

Buy Neurocrine Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you open a Robinhood account
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Neurocrine Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Neurocrine Biosciences price performance over time

Historical closes compared with the close of $99.25 from 2022-07-01

1 week (2022-06-29) 0.80%
1 month (2022-06-06) 5.41%
3 months (2022-04-04) 1.79%
6 months (2022-01-06) 20.26%
1 year (2021-07-06) 1.85%
2 years (2020-07-06) -22.25%
3 years (2019-07-05) 16.50%
5 years (2017-07-06) 111.89%

Is Neurocrine Biosciences stock undervalued or overvalued?

Valuing Neurocrine Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Neurocrine Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Neurocrine Biosciences's P/E ratio

Neurocrine Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 132x. In other words, Neurocrine Biosciences shares trade at around 132x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Neurocrine Biosciences's PEG ratio

Neurocrine Biosciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.87. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Neurocrine Biosciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Neurocrine Biosciences's EBITDA

Neurocrine Biosciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $191.1 million.

The EBITDA is a measure of a Neurocrine Biosciences's overall financial performance and is widely used to measure a its profitability.

Neurocrine Biosciences financials

Revenue TTM $1.2 billion
Operating margin TTM 14.86%
Gross profit TTM $791.1 million
Return on assets TTM 5.62%
Return on equity TTM 5.5%
Profit margin 5.91%
Book value $14.57
Market capitalisation $9.3 billion

TTM: trailing 12 months

Neurocrine Biosciences share dividends

We're not expecting Neurocrine Biosciences to pay a dividend over the next 12 months.

Neurocrine Biosciences share price volatility

Over the last 12 months, Neurocrine Biosciences's shares have ranged in value from as little as $71.88 up to $108.02. A popular way to gauge a stock's volatility is its "beta".

NBIX.US volatility(beta: 0.7)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neurocrine Biosciences's is 0.6956. This would suggest that Neurocrine Biosciences's shares are less volatile than average (for this exchange).

Neurocrine Biosciences overview

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia.

Frequently asked questions

What percentage of Neurocrine Biosciences is owned by insiders or institutions?
Currently 1.337% of Neurocrine Biosciences shares are held by insiders and 99.032% by institutions.
How many people work for Neurocrine Biosciences?
Latest data suggests 1,100 work at Neurocrine Biosciences.
When does the fiscal year end for Neurocrine Biosciences?
Neurocrine Biosciences's fiscal year ends in December.
Where is Neurocrine Biosciences based?
Neurocrine Biosciences's address is: 12780 El Camino Real, San Diego, CA, United States, 92130
What is Neurocrine Biosciences's ISIN number?
Neurocrine Biosciences's international securities identification number is: US64125C1099
What is Neurocrine Biosciences's CUSIP number?
Neurocrine Biosciences's Committee on Uniform Securities Identification Procedures number is: 64125C109

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site